Immunomedics, Inc (IMMU)
Immunomedics, Inc. is a biopharmaceutical company, focused on the development of monoclonal antibody-based products for the treatment of cancer, autoimmune and other serious diseases. The compnay develops technologies, allowing to create humanized antibodies, that can be used either alone, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents A product candidate of the compnay was epratuzumab, developed for the treatment of patients with moderate and severe lupus and licensed to UCB S.A. Other products include IMMU-106, which is in Phase I/II clinical trials in patients with B-cell non-Hodgkin's...
read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Contact Information:
| Business Address: | - |
| Mailing Address: | 300 AMERICAN ROAD MORRIS PLAINS NJ 07950 Business Address 300 AMERICAN RD MORRIS PLAINS NJ 07950 9736058200 IMMUNOMEDICS INC CIK #: 0000722830 (see |
| Phone: | 973-605-8200 |
| Fax: | 973-605-8282 |
| Website: | http://www.immunomedics.com |
Company Details:
| Symbol: | IMMU |
| SIC: | - |
| State location: | NJ |
| Sector: | - |
| State of Inc: | DE |
| Employees: | 122 |
| Type: | NASDAQ |
Key executives:
| Name | Age | Position |
|---|---|---|
| Chau Cheng | - | Associate Director of Investor Relations & Bus. Analysis |
| Cynthia L. Sullivan | 56 | Chief Exec. Officer, Pres, Director, Member of Exec. Committee and Acting Pres of IBC Pharmaceuticals Inc |
| David M. Goldenberg | 74 | Founder, Chairman, Chief Strategic Officer, Member of Exec. Committee of IBC Pharmaceuticals Inc |
| Gerard G. Gorman | 61 | Chief Financial Officer, Principal Accounting Officer, Sr. VP of Bus. Devel. & Finace and Treasurer of IBC Pharmaceuticals Inc |
| Phyllis Parker | - | Sec. and Sec. of IBC Pharmaceuticals Inc |
Immunomedics, Inc. (NASDAQ:IMMU) Loses Investor Interest on the Ongoing PR May 27, 2010
Immunomedics, Inc. (NASDAQ:IMMU) continues the sharp depreciation with another 3.35% decline yesterday. Considerably underperforming its healthcare industry, the under $5 stock closed at $3.17 for a share on investors ignoring the continuous PR and having doubts about the profitability of the company.read more
| Post # | Subject | Re | Name | Date |
|---|---|---|---|---|
| 1 | Read the latest news on the company:... | 0 | Keye | July 02, 2008, 02:05AM |
| 2 | Here on this message board we are inviting... | 0 | Guest | July 02, 2008, 02:05AM |